Empara’s virtual assistant is the latest attempt to use AI to simplify the user experience in the healthcare industry.
Empara
Navigating healthcare benefits can be difficult for many people. One company is hoping that AI can make this process easier.
Empara, a healthcare technology company, announced that it has launched an AI-powered virtual assistant designed to make it easier for users of Empara’s digital health platform to navigate their benefits.1 The company also says the virtual assistant can be used by service providers and HR teams to increase efficiency on their end.
According to Empara, the assistant can be trained on specific company handbooks and specific documentation.
In a press release, Empara’s president Markus Waite said, “When it comes to the complexity of health benefits, there are many questions that arise. Em knows the answers and provides instant responses to help members find the information they need quickly. It integrates seamlessly with a group's existing benefits and handles the routine inquiries, freeing up administrators to focus on other strategic initiatives."
Waite continued, “With turnkey efficiency, we enable our customers to deploy their own customized AI assistants—putting them at the forefront of the AI revolution—all backed by the power of the Empara Health Engagement platform.”
Empara’s chief experience officer Ben Callaghan also said, “How much time are your member service or HR teams spending answering questions like, 'Is this covered?' or, 'I need shoulder surgery and I don't understand what I will have to pay.'Our clients experience a dramatic reduction in call and email volume because members can message Em and get instant, well-defined responses about their specific plan and usage."
Mike Nigels, chief technology officer, said, “AI is fundamentally changing how software is developed and how people interact with their apps and devices. It's an especially powerful tool in the healthcare and benefits space because of its ability to interpret, analyze and summarize complex concepts. We've harnessed that power to serve up personalized and powerful insights that can provide members with significant savings on the cost of their healthcare while simplifying access to their benefits."
Empara first announced its digital platform in October of 2023.2 At the time, the platform was described as being designed to improve the self-funded healthcare plan marketplace and make it easier to navigate.
In a press release issued at the time, Waite said, “Empara's Health Engagement Platform will power the next generation of self-funded health plans and the partners that serve them, such as TPAs and benefit brokers. TPAs and benefit consultants create many innovative programs for their employer groups, but the maze of point solutions and multiple apps and portals makes member engagement a challenge."
Waite continued, “The feature that is becoming the most critical is our message center, which allows members to engage with the different care organizations that service their health plan such as their TPA, benefit navigator, virtual MD or clinical pharmacy team. Our goal is to simplify a member's benefits in one place, driving utilization and engagement in their health benefits that will lead to better outcomes and lower costs for the group and their members."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.